Abstract
For accelerator targets, graphene films are an excellent material choice due to their high thermal conductivity, high temperature tolerance, low outgassing, mechanical integrity, and ease of handling. A variety of targets have been produced using graphene material as a backing or a host matrix. One of the unique advantages of the graphene film fabrication process is the capability to embed target materials, including refractory metals, in the nanoparticle form into a host graphene matrix during target preparation. Targets of natIr and natRe have been fabricated as nanoparticle loaded graphene targets for use in nuclear physics research. We have obtained beam time to evaluate target performance as well as production yields and nuclear decay properties via the natRe(a,2n)186Ir and natIr(a,3n)194Au reactions, respectively. These rhenium and iridium targets will be irradiated using the ATLAS accelerator and gamma rays measured in-place using the high-precision gamma-ray spectroscopy capabilities of Gammasphere and further analyzed using a multi-parameter detector system. Future plans include the preparation of isotopic targets of these two elements.
Highlights
Introduction and motivationWith cancer incidence rates continuing to climb, research into advanced, diagnostic and therapeutic radiopharmaceuticals is critical to meeting future needs [1]
Incorporation of the Auger-emitting 186Ir (t1/2 = 16.64 h) could lead to a synergistic killing effect improving the overall treatment by reducing the required dose of the chemotherapeutic agent
Rhenium was first discovered in platinum ores by Noddack, Tacke and Beer in 1925 [10]
Summary
With cancer incidence rates continuing to climb, research into advanced, diagnostic and therapeutic radiopharmaceuticals is critical to meeting future needs [1]. In this regard, a theranostic drug allows for low dose imaging and dosimetry estimates followed by a tailored course of therapeutic treatments based on the diagnostic evaluation. A theranostic drug allows for low dose imaging and dosimetry estimates followed by a tailored course of therapeutic treatments based on the diagnostic evaluation The success of this approach is dependent on high specific activity radionuclides. Auger-emitting 194Au (t1/2 = 38.02 h) can provide the same synergistic killing effect and SPECT imaging (γ = 328.5 keV, 60.4%; 293.5 keV, 10.6%) for gold-based anti-cancer drugs. Production rates of 12.9 μCi/nAh and 20.8 μCi/nAh are expected for 186Ir and 194Au, respectively
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
